Tags : PhoreMost

PharmaShots Weekly Snapshot (January 20-24, 2020)

1. Epizyme’s Tazverik (tazemetostat) Receives the US FDA’s Accelerated Approval as the First Therapy for Epithelioid Sarcoma Published: Jan 23, 2020 | Tags: Epizyme, Tazverik, tazemetostat, Receives, US, FDA, Accelerated Approval, First Therapy, Epithelioid Sarcoma 2. Evarsana Signs an Agreement with Evoke Pharma to Commercialize Gimoti in the US Published: Jan 23, 2020 | Tags: Evarsana, Signs, […]Read More

PhoreMost Signs Multi-Project Drug Discovery Collaboration with Otsuka Pharmaceutical to

Shots: The companies collaborated to identify targets for Otsuka’s therapeutics discovery programmes by leveraging PhoreMost’s expertise and next-generation phenotypic screening platform, SITESEEKER Otsuka will validate the novel targets identified in the collaboration as part of its internal development pipeline with an initial focus on gene therapy applications of identified targets  PhoreMost’s SITESEEKER platform deploys protein […]Read More

PharmaShots Weekly Snapshot (January 06-10, 2020)

Nektar Therapeutics Signs a Clinical Trial Collaboration with Bristol-Myers Squibb Published: Jan 10, 2020 | Tags: Nektar Therapeutics, Signs, Clinical Trial, Collaboration, Bristol-Myers Squibb 2. Eli Lilly to Acquire Dermira for $1.1B Published: Jan 10, 2020 | Tags: Eli Lilly, Acquire, Dermira, $1.1B 3. Bayer Signs a Three Year Multi Target AI-based Agreement with Exscientia to Treat […]Read More

PhoreMost Signs a Multi-Project Drug Discovery Agreement with Boehringer Ingelheim

Shots: PhoreMost to receive upfront and research funding plus milestones and will utilize its expertise and phenotypic screening platform, SITESEEKER for the targets identified by BI and will be further included in and validated in BI’s pipeline The focus of the agreement is to enhance BI’s drug discovery pipeline utilizing PhoreMost’s PROTEINi and SITESEEKER platform […]Read More

C4X Discovery Signs a Neurodegeneration Drug Discovery Agreement with PhoreMost

Shots: The agreement collaborates C4XD’s Taxonomy3 (target identification platform) with PhoreMost’s SITESEEKER (screening platform) to accelerate drug discovery initially focusing on Parkinson’s disease with expected profit sharing by both the companies on validated targets The focus of the agreement is to advance C4XD drug discovery pipeline by validating targets identified by C4XD’s Taxonomy3 with the […]Read More